Thermo Fisher Scientific is no stranger to M&A.; In the past few years, the company has struck a series of deals to beef up in diagnostics, including its $13.6 billion pact for DNA sequencing giant Life Technologies. Now Thermo Fisher could be revving up its dealmaking engine again, one analyst says.
VCA said on February 29 that it would buy up an 80% stake in Companion Animal Practices North America, a Las Vegas-based chain of 56 veterinary hospitals.
Battle-weary Toshiba is barreling toward the finish line in a sale of its medical device unit, and fellow Japanese devicemaker Fujifilm could emerge the winner in a potential $6 billion deal.
The site management organization Synexus has strengthened its global reach with the acquisition of Research Across America, marking its arrival into the lucrative U.S. market.
In the latest chapter of med tech M&A;, Swedish private equity firm EQT Holdings is putting local medical device company Atos Medical up for sale for about €1 billion ($1.1 billion).
Sanofi made a splash in rare disease R&D; when it traded $20 billion for Genzyme in 2011, and now the French drugmaker is on the hunt for deals "up to" that size as acquisitive rival Shire angles to dominate the space.
Long-beleaguered Toshiba is planning on selling its entire medical equipment unit as it grapples with rising restructuring costs. The move comes as the Japanese company attempts to recover from an accounting scandal that has taken a hefty toll on business.
Cipla closed a $550 million deal last week that got the Indian drugmaker its first U.S. manufacturing facility and a bunch of new products. Cipla's deal was just one of more than 30 that Indian drugmakers have made in the U.S. in the last the 5 years as they seek to get their hands on technology that would be hard to duplicate in India.
Recipharm has been continent-hopping to do a series of deals that expand both its geographic reach and its capabilities. Last fall, it struck a deal to buy an Indian company, and now the Sweden-based contract manufacturer says it is snapping up an antibiotics specialist in Italy.
Big-time Pfizer investors are no doubt prepared for the tax hit from its forthcoming merger with Allergan. But smaller shareholders, including current and retired employees, could face tax liabilities they're not ready for.